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Background: Some RCT have shown cilostazol in addition to aspirin and thienopyridine after percutaneous coronary intervention (PCI) decrease 
the event rate of TLR, particularly in case of sirolims eluting stents. But the efficacy and safety of triple antiplatelet therapy for complex patient in 
real clinical practice are not clear. 
Method: Prospectively collected data of Japanese 12,824 patients received PCI in j-Cypher Registry were analyzed. We compared 12,038 that have 
received double antiplatelet therapy at the time of discharge (aspirin+thienopyridine) with 266 have received triple antiplatelet therapy (aspirin+thie
nopyridine+cilostazol). 33 stent thrombosis occurred until discharge were excluded. 
Result: Patient received triple antiplatelet therapy have more comorbidities, such as poor Euroscore, Aorta/Peripheral artery disease, hemodyalysis, 
insulin dependent diabetes mellitus, PCI for left main trunk (Table 1). The cardiovascular event rates including TLR, hospitalization for heart failure 
were not significantly different between the two groups after adjustment of the differences in baseline characteristics (Table 2). 
Conclusions: Patients received triple antiplatelet therapy had more comorbidities in j-Cypher Registry. The efficacy of triple antiplatelet therapy for 
reducing the event rate of TLR is controversial in Japanese real-world clinical practice. 
Table1. Baseline Characteristics
Baseline characteristics
Double antiplatelet therapy
(n=12,038)
Triple antiplatelet therapy
(n=266)
p
Age, Year 68.3±10.2 68.2±10.9 0.86
Male, % 75.7 75.9 1
Body mass index 24 23.4 0.0055
Euroscore 4.5 5.2 0.0002
Aorta/Peripheral artery disease,% 11.4 25.9 <0.0001
Hemo dialysis,% 5.0 12.7 <0.0001
Hypertention,% 74.5 80.0 0.0456
Insulin dependent diabetes mellitus,% 9.2 15.4 0.0013
History of heart failure,% 13.3 14.2 0.64
Left main trunk,% 5.2 9.8 0.0032
Table2. Cardiac Event Rate
Double Antiplatelet Therapy
(n=12,038) %
Triple Antiplatelet Therapy
(n=266) %
p
Adjusted Hazard Ratio(95% Confidence 
Interval)
p
All-cause mortality 8.67 8.31 0.63 0.87(0.50-1.38) 0.59
Cardiac death 3.81 4.23 0.42 1.27(0.60-2.32) 0.50
All AMI 3.31 2.49 0.76 0.81(0.32-1.67) 0.61
Hospitalization for heart failure 6.64 7.81 0.61 0.97(0.53-1.62) 0.94
Stroke 4.09 4.02 0.90 0.91(0.43-1.66) 0.79
TLR 13.81 15.44 0.39 0.96(0.67-1.32) 0.22
Stent thrombosis 0.75 1.13 0.47 1.90(0.46-5.13) 0.37
